comparemela.com

Latest Breaking News On - Supported dose escalation - Page 1 : comparemela.com

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101.

United statesStacy nartkerWildon farwellAmy reillyValeriaa sansoneJoshua brummLos angelesPerry shiehExchange commissionGene panelDyne therapeutics incMyotonic dystrophy health indexDavid geffen school of medicineEuropean medicines agencyUniversity of milanClinical center ne

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown -

United statesWildon farwellJoshua brummStacy nartkerValeriaa sansoneAmy reillyPerry shiehLos angelesDavid geffen school of medicineEuropean medicines agencyUniversity of milanExchange commissionDyne therapeutics incDrug administrationMyotonic dystrophy health indexGene panel

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

- Initial ACHIEVE and DELIVER Data to be Presented at a Company Event Around the J.P. Morgan Healthcare Conference in Early January 2024, Including Safety, Biomarker of Splicing and Functional Outcome.

Joshua brummAmy reillyStacy nartkerExchange commissionCompany eventDyne therapeutics incCompany event aroundHealthcare conferenceEarly januaryIncluding safetyFunctional outcomeDystrophin expressionEnrolled throughSupported dose escalationCombined nine cohortsInitial data

vimarsana © 2020. All Rights Reserved.